GlassScriptPhysician profile
Alissa Mcinerney
NPI 1205281920
$37,857.73
in general payments reported to CMS, 2019-2025
32 companies · $26K in 2025
The $26K reported for 2025 was more than what 93% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $16.86 · 2021: $314 · 2022: $708 · 2023: $2,226 · 2024: $8,158 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Food and Beverage: $11K · Travel and Lodging: $2,435 · Education: $23.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,479.00 |
| Food and Beverage | $11,159.52 |
| Travel and Lodging | $2,434.66 |
| Education | $23.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $23,506.87 | 2019-2025 | |
| Genentech USA, INC. | $4,233.42 | 2024-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $2,292.23 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,482.74 | 2023-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,475.84 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,350.35 | 2022-2025 | Tezspire, Airsupra, Fasenra |
| Leo Pharma INC. | $799.62 | 2022-2025 | Adbry, Anzupgo |
| Blueprint Medicines Corporation | $425.26 | 2024-2025 | Ayvakit |
| Alk-Abello, INC | $370.13 | 2021-2025 | Grastek, Odactra, Ragwitek |
| Abbvie INC. | $212.65 | 2023-2025 | |
| Amgen INC. | $175.88 | 2023-2025 | Tezspire |
| Kaleo, INC. | $171.17 | 2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $150.63 | 2025 | Neffy |
| Genentech, INC. | $149.96 | 2024 | Xolair |
| Optinose US, INC. | $147.35 | 2021-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greer Laboratories, INC. | $116.48 | 2024-2025 | Palforzia, Oralair |
| Regeneron Pharmaceuticals, INC. | $102.79 | 2023-2025 | Dupixent |
| Galderma Laboratories, L.P. | $83.23 | 2025 | Nemluvio |
| Takeda Pharmaceuticals U.S.A., INC. | $79.42 | 2020-2024 | Cuvitru |
| Biocryst US Sales Co., LLC | $75.11 | 2024-2025 | Orladeyo |
| Organon LLC | $62.33 | 2025 | Vtama |
| Lilly USA, LLC | $60.65 | 2025 | Ebglyss |
| Grifols USA, LLC | $59.55 | 2024-2025 | Xembify |
| Aerin Medical INC. | $54.84 | 2023-2025 | |
| Pfizer INC. | $40.86 | 2023-2024 | |
| Pharming Healthcare, INC. | $37.64 | 2024 | Ruconest |
| Phathom Pharmaceuticals, INC. | $34.11 | 2024 | Voquezna |
| Dermavant Sciences, INC. | $33.32 | 2024 | Vtama |
| Intersect Ent, INC. | $20.43 | 2022 | |
| Csl Behring | $19.55 | 2024 | Hizentra |
| Hikma Pharmaceuticals USA | $18.50 | 2024 | Ryaltris |
| Astellas Pharma US INC | $14.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alissa Mcinerney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.